Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11846946 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL4450989 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL369243 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL25518782 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL6725173 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL18545315 | 0.81 | TAAR1 (0.42) | ALDH1A1KDM4ELMNATAAR1TRPA1 | |
| SCHEMBL1792962 | 0.80 | PTGES2 (0.44) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL3083627 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL18028833 | 0.80 | PTGES2 (0.44) | ALDH1A1KDM4ELMNAGMNNPOLB | |
| SCHEMBL16399485 | 0.80 | LMNA (0.41) | ALDH1A1KDM4ELMNAGMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| EP-4108663-A1 | SUBSTITUTED ARYL COMPOUND | Simcere Pharmaceutical Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| CN-110483344-B | Cycloalkyl-containing beta-hydroxy sulfone compound and synthesis method thereof | 辽宁石油化工大学 | 2021-06-18 | — | — | CN | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| US-9814722-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011079091-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR THERAPEUTICAL USES | CELGENE CORPORATION (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079091-A1 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR THERAPEUTICAL USES | CELGENE CORPORATION (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010053182-A1 | KYNURENINE PRODUCTION INHIBITOR | 協和発酵キリン株式会社 (JP) | 2010-05-14 | — | — | WO | disclosed |
| US-7632852-B2 | (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080004443-A1 | Sulfonated polyaryletherketone-block-polyethersulfone copolymers | GENERAL ELECTRIC COMPANY | 2008-01-03 | — | — | US | disclosed |
| EP-0086678-A1 | Process for the preparation of 2-acyl-1,3,4,6,7,11b-2H-hexahydro-4-pyrazino(2,1-a)isoquinolinones and intermediates | ELF SANOFI (FR) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885KDM4E 528/4885LMNA 4785/4885 |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | DHFR, DPYD, THPO | ALDH1A1 23/4885KDM4E 1047/4885LMNA 3420/4885 |
| US-20080004443-A1 | Sulfonated polyaryletherketone-block-polyethersulfone copolymers | ABCB7, AKR1B10, RER1 | ALDH1A1 2050/4885KDM4E 4420/4885LMNA 2259/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | ALDH1A1 1689/4885KDM4E 755/4885LMNA 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.